CONCERTA ® should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behavior. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder that may require follow-up.
CONCERTA® (methylphenidate HCl)
Extended-release Tablets CII
CONCERTA® is a central nervous system (CNS) stimulant.
CONCERTA® is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
The efficacy of CONCERTA® in the treatment of ADHD was established in three controlled trials of children aged 6 to 12 who met DSM-IV criteria for ADHD (see CLINICAL PHARMACOLOGY).
A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, eg, in social, academic, or occupational functioning, and be present in two or more settings, eg, school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet
activities; "on the go;" excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.
Special Diagnostic Considerations
Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use of medical and special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM-IV characteristics.
Need for Comprehensive Treatment Program
CONCERTA® is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the child's symptoms.
The effectiveness of CONCERTA® for long-term use, ie, for more than 4 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use CONCERTA® for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).
Media Articles Related to Concerta (Methylphenidate)
Daytrana ADHD Patch May Cause Permanent Skin Color Changes
Source: Medscape Psychiatry & Mental Health Headlines [2015.06.24]
The methylphenidate patch Daytrana for ADHD may cause permanent skin color loss, the FDA warns.
Published Studies Related to Concerta (Methylphenidate)
Drug-specific laterality effects on frontal lobe activation of atomoxetine and
methylphenidate in attention deficit hyperactivity disorder boys during working
CONCLUSIONS: The study shows both shared and drug-specific effects. ATX
Effect of methylphenidate and folic Acid on ADHD symptoms and quality of life and
aggression: a randomized double blind placebo controlled clinical trial. 
CONCLUSION: considering the marked limitations of this trial, this primarily
Effects of methylphenidate on acute math performance in children with
attention-deficit hyperactivity disorder. 
CONCLUSIONS: MPH improves acute math performance in children with ADHD. Younger
Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of
attention, behavior, and performance benefits in children with
attention-deficit/hyperactivity disorder. 
performance in children with attention-deficit/hyperactivity disorder... CONCLUSIONS: D-MPH-ER 30 mg was superior to D-MPH-ER 20 mg at later time points
A post hoc comparison of the effects of lisdexamfetamine dimesylate and
osmotic-release oral system methylphenidate on symptoms of attention-deficit
hyperactivity disorder in children and adolescents. 
methylphenidate (OROS-MPH) on symptoms of ADHD in children and adolescents... CONCLUSIONS: This post hoc analysis showed that, at the doses tested, patients
Clinical Trials Related to Concerta (Methylphenidate)
A Double-Blind Randomized, Placebo-Controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-Acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults [Completed]
This is a double-blind, placebo-controlled study, three-period crossover study to examine the
likeability of a single dose of OROS MPH (CONCERTẢ 90mg) and a single dose of Long-acting
MPH (RITALIN LẢ 90mg). Hypotheses are as follows:
Hypothesis 1: OROS-MPH (CONCERTẢ) will be later than SODOS-MPH (RITALIN LẢ) in its Tmax
(time to Cmax).
Hypothesis 2: The subjective feelings of detection and likeability would be greater for
SODOS-MPH (RITALIN LẢ) than for an equivalent total dose of OROS-MPH (CONCERTẢ).
Naturalistic Substitution of Concerta in Adult Subject With ADHD Receiving Immediate Release Methylphenidate [Completed]
This is a single-blind study looking at the efficacy and satisfaction of Concerta
substitution in adult subjects with ADHD receiving immediate release methylphenidate.
Subjects will be administered a maximum dose of 1. 3mg/kg/day of either methylphenidate or
Concerta. The specific hypotheses of this study are:
Hypothesis 1: ADHD symptomatology in adults with DSM-IV, ADHD will continue to be controlled
in patients switched from MPH IR TID to Concerta.
Hypothesis 2: Patient satisfaction will not decrease in patients switched from MPH IR TID to
Concerta (ie., all patients will be equally or more satisfied on Concerta as compared with
MPH IR TID.
An Effectiveness and Safety Study Evaluating OROS® Methylphenidate HCl, Ritalin® (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder [Completed]
The purpose of this study is to provide data on the effectiveness of the OROS®
Methylphenidate HCl formulation compared to placebo and standard immediate-release Ritalin®
with respect to improving attention and behavior, and decreasing hyperactivity in children
with Attention Deficit Hyperactivity Disorder (ADHD). Both OROS® Methylphenidate HCl and
Ritalin® contain the central nervous system stimulant, methylphenidate HCl. The safety
associated with the two methylphenidate formulations will also be compared with placebo.
A Comparative Effectiveness Study Evaluating OROS® Methylphenidate HCl, Ritalin® (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children [Completed]
A Multicenter Study Comparing the Efficacy and Safety of OROS® Methylphenidate HCl, Ritalin® (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder [Completed]
The purpose of this study is to evaluate the efficacy and safety of OROS® Methylphenidate HCl
as compared with placebo and standard immediate-release Ritalin® (taken three time per day)
for the treatment of Attention Deficit Hyperactivity Disorder in children. Both OROS®
Methylphenidate HCl and Ritalin® contain the central nervous system stimulant,
Reports of Suspected Concerta (Methylphenidate) Side Effects
Drug Ineffective (34),
Suicidal Ideation (31),
Abnormal Behaviour (26),
Decreased Appetite (25),
Psychotic Disorder (21),
Drug Dose Omission (19),
Growth Retardation (17), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 14 ratings/reviews, Concerta has an overall score of 6.29. The effectiveness score is 7.43 and the side effect score is 6.86. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
Concerta review by care giver of 13 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || ADD|
|Dosage & duration:|| || 27 MG taken daily for the period of 5 YEARS|
|Other conditions:|| || N/A|
|Other drugs taken:|| || N/A|
|Benefits:|| || As an ADD child unable to process information propertly, the medication helped her get focused and understand better while in school. Her anxiety level was controlled and helped loose some weight. She was able to control better the outburst socially.|
|Side effects:|| || some slight headaches and lacking energy, complainingof being tired.|
|Comments:|| || Medication was prescribed while in second grade. Socially and academically it helped her quite significantly. In school she was in special classes and the medicationhas helped her get mainstreamed into regular classes. She is able to soialize a bit better along with therapy. Her level of anxiety is better making her behave a little more relaxed and controlling regular outbursts. It also helped her in her weight due to the anxiety control. Definately able to see the difference when not taking the medication. Difficult to be in school without it.|
Concerta review by 35 year old male patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || ADHD|
|Dosage & duration:|| || 27 mg taken once daily for the period of 3 months|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || I was able to concentrate and complete daily tasks. I didn't have to write notes to myself and constantly put them in various places so I would run into during the day.l|
|Side effects:|| || I get a bit irritable when the medication wears off for about 30 minutes. I also feel quite tired during this time.|
|Comments:|| || My primary care physician prescribe it after telling him my problems I've had my entire life in concentrating/completing tasks. I was also very forgetful but don't have any of these problems except on occasion when I have too many things going on.|
Concerta review by 39 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Ineffective|
|Side effects:|| || Severe Side Effects|
|Condition / reason:|| || ADHD|
|Dosage & duration:|| || 18 mg taken 1 a day for the period of 2 days|
|Other conditions:|| || Depression|
|Other drugs taken:|| || Lexapro, Lamactol , Clonzapam|
|Benefits:|| || None! |
|Side effects:|| || Felt like I was speeding out of my mind. I couldn't function, forgot to go to work on time, rectol bleeding, felt like I couldn't breathe, still rectol bleeding after not taking it for 2 days. Have slept alot since not taking it. This had horrible side effects for me from the start. I read the reviews and see I am a older person taking this drug, but I Don't see how anyone could normally function on this drug. I didn't know if I was coming or going and it also made me feel akward when driving. Dangerous drug! |
|Comments:|| || >>|
Page last updated: 2015-06-24